KDA Treatment Guidelines for Diabetes
- Page path
-
- Home
- Resources
- KDA Treatment Guidelines for Diabetes
- Resources
KDA Treatment Guidelines for Diabetes
- Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
-
- 2020.03.17
- Hit 912
- https://e-dmj.org/search.php?where=aview&id=10.4093/dmj.2017.41.5.337&code=2004DMJ&vmode=FULL (클릭 112회)
Open Access
| Diabetes Metab J. 2017 Oct;41(5):337-348. English. Published online Oct 17, 2017. https://doi.org/10.4093/dmj.2017.41.5.337 |
|
| Copyright © 2017 Korean Diabetes Association | |
| Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association | |
Seung-Hyun Ko,1,* Kyu-Yeon Hur,2,* Sang Youl Rhee,3 Nan-Hee Kim,4 Min Kyong Moon,5 Seok-O Park,6 Byung-Wan Lee,7 Hyun Jin Kim,8 Kyung Mook Choi , 4 Jin Hwa Kim,9 and Committee of Clinical Practice Guideline of Korean Diabetes Association |
|
| 1Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. | |
| 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. | |
| 3Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. | |
| 4Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. | |
| 5Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. | |
| 6Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea. | |
| 7Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. | |
| 8Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. | |
| 9Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea. | |
|
Corresponding author: Kyung Mook Choi. Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea.
*Seung-Hyun Ko and Kyu-Yeon Hur contributed equally to this study as first authors. |
|
| Received August 25, 2017; Accepted September 15, 2017. |
|
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
|
 This article has been cited by 5 articles in   This article has been cited by 14 articles in KoMCI. This article has been cited by Google Scholar. This article has been cited by 7 articles in PubMed Central. This article has been cited by 17 articles in Scopus. This article has been cited by 15 articles in Web of Science. |
|
|
Abstract
|
|
In 2017, the Korean Diabetes Association (KDA) published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). The KDA regularly updates its Clinical Practice Guidelines, but since the last update in 2015, many results from clinical trials have been introduced, and domestic data from studies performed in Korean patients with T2DM have been published. Recently, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations. Additionally, new data from clinical trials using dipeptidyl peptidase 4 inhibitors and thiazolidinediones in Korean patients with T2DM were added. Following a systematic review and assessment of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the use of antihyperglycemic agents and revised the treatment algorithm for Korean adult patients with T2DM. |
|
|
Keywords:
Diabetes mellitus, type 2; Hypoglycemic agents; Insulin; Practice guideline
|
|